Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.52 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.49 |
| ▸ | BRD3 | Q15059 | 4/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | ATM | Q13315 | 1/20 | 0.46 |
| ▸ | MAPKAPK2 | P49137 | 4/20 | 0.45 |
| ▸ | MAPKAPK5 | Q8IW41 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | CASP6 | P55212 | 1/20 | 0.42 |
| ▸ | DHODH | Q02127 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4024670 | 0.88 | CYP2D6 (0.54) | SIRT1CYP2D6BRD3KCNH2MAPT | |
| SCHEMBL4023608 | 0.82 | CYP2D6 (0.53) | SIRT1CYP2D6BRD3KCNH2MAPT | |
| SCHEMBL4172365 | 0.81 | CYP2D6 (0.60) | SIRT1CYP2D6BRD3KCNH2MAPT | |
| SCHEMBL4025827 | 0.80 | MEN1 (0.54) | SIRT1CYP2D6BRD3KCNH2MAPT | |
| SCHEMBL4028639 | 0.79 | CYP2D6 (0.67) | SIRT1CYP2D6BRD3KCNH2MAPT | |
| SCHEMBL4025034 | 0.79 | CYP2D6 (0.71) | SIRT1CYP2D6BRD3KCNH2MAPT | |
| SCHEMBL4028422 | 0.79 | CYP2D6 (0.50) | SIRT1CYP2D6BRD3KCNH2MAPT | |
| SCHEMBL4152166 | 0.79 | CYP2D6 (0.61) | SIRT1CYP2D6BRD3KCNH2MAPT | |
| SCHEMBL31120775 | 0.79 | BRD3 (0.72) | SIRT1BRD3MAPTALOX15MAPK1 | |
| SCHEMBL4152213 | 0.78 | BRD3 (0.75) | SIRT1CYP2D6BRD3KCNH2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1646610-B1 | TETRAHYDROCARBAZOLE DERIVATIVES AND THEIR PHARMACEUTICAL USE | SMITHKLINE BEECHAM CORP (US) | 2009-07-22 | — | — | EP | claimed |
| US-7419997-B2 | Tetrahydrocarbazole derivatives and their pharmaceutical use | SMITHKLINE BEECHAM CORPORATION (US) | 2008-09-02 | — | — | US | claimed |
| US-20060148857-A1 | Tetrahydrocarbazole derivatives and their pharmaceutical use | SMITHKLINE BEECHAM CORPORATION | 2006-07-06 | — | — | US | claimed |
| EP-1646610-B1 | TETRAHYDROCARBAZOLE DERIVATIVES AND THEIR PHARMACEUTICAL USE | SMITHKLINE BEECHAM CORP (US) | 2009-07-22 | — | — | EP | disclosed |
| EP-1646610-B1 | TETRAHYDROCARBAZOLE DERIVATIVES AND THEIR PHARMACEUTICAL USE | SMITHKLINE BEECHAM CORP (US) | 2009-07-22 | — | — | EP | disclosed |
| US-20090170906-A1 | HCV INHIBITORS | SMITHKLINE BEECHAM CORPORATION | 2009-07-02 | — | — | US | disclosed |
| US-20090170906-A1 | HCV INHIBITORS | SMITHKLINE BEECHAM CORPORATION | 2009-07-02 | — | — | US | disclosed |
| US-20090170906-A1 | HCV INHIBITORS | SMITHKLINE BEECHAM CORPORATION | 2009-07-02 | — | — | US | disclosed |
| US-7419997-B2 | Tetrahydrocarbazole derivatives and their pharmaceutical use | SMITHKLINE BEECHAM CORPORATION (US) | 2008-09-02 | — | — | US | disclosed |
| US-7419997-B2 | Tetrahydrocarbazole derivatives and their pharmaceutical use | SMITHKLINE BEECHAM CORPORATION (US) | 2008-09-02 | — | — | US | disclosed |
| US-7419997-B2 | Tetrahydrocarbazole derivatives and their pharmaceutical use | SMITHKLINE BEECHAM CORPORATION (US) | 2008-09-02 | — | — | US | disclosed |
| US-20060148857-A1 | Tetrahydrocarbazole derivatives and their pharmaceutical use | SMITHKLINE BEECHAM CORPORATION | 2006-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090170906-A1 | HCV INHIBITORS | HAVCR2, MAVS, EIF2AK2 | SIRT1 418/4885CYP2D6 994/4885BRD3 4059/4885 |
| US-20060148857-A1 | Tetrahydrocarbazole derivatives and their pharmaceutical use | HMBS, UGT2B17, TPMT | SIRT1 1590/4885CYP2D6 660/4885BRD3 22/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.